A rare atypical myeloproliferative-disorder-like hemopathy with marked dysplasia, peripheral dominant myeloblast proliferation and extramedullary hematopoiesis was converted into typical acute myeloid leukemia with an interval of complete hematological remission

Int J Hematol. 1998 Jun;67(4):411-6. doi: 10.1016/s0925-5710(98)00013-9.

Abstract

We describe a patient with leukocytosis with all the stages of neutrophilic series, peripheral dominant myeloblast proliferation, marked dysplasia of myeloid and erythroid series, and extramedullary hematopoiesis of the lymph nodes. A cytogenetic study of the bone marrow cells showed normal karyotype, and molecular analysis of the leukemic cells showed negative for BCR-ABL by RT-PCR. After chemotherapy, the patient went into complete remission with a normal blood and bone marrow profile with no dysplasia. On relapse, the hematological findings showed a typical bone marrow dominant acute myeloid leukemia, with the leukemic cells having a chromosomal abnormality. The patient exhibited the combined features of myeloproliferative disorder, myelodysplastic syndrome, peripheral dominant myeloblast proliferation (so-called peripheral leukemia) and typical acute myeloid leukemia throughout the clinical course. This is thought to be a rare overlapping disease involving these distinct hematological conditions that do not usually occur in the same patient.

Publication types

  • Case Reports

MeSH terms

  • Acute Disease
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Bone Marrow / pathology
  • Cytarabine / administration & dosage
  • Cytarabine / analogs & derivatives
  • Daunorubicin / administration & dosage
  • Disease Progression
  • Hematopoiesis, Extramedullary
  • Humans
  • Leukemia, Myeloid / pathology*
  • Male
  • Mercaptopurine / administration & dosage
  • Middle Aged
  • Myelodysplastic Syndromes / drug therapy
  • Myelodysplastic Syndromes / pathology*
  • Myeloproliferative Disorders / drug therapy
  • Myeloproliferative Disorders / pathology*
  • Prednisolone / administration & dosage
  • Preleukemia / pathology*
  • Remission Induction

Substances

  • Cytarabine
  • Prednisolone
  • Mercaptopurine
  • Daunorubicin

Supplementary concepts

  • BH-AC-DMP protocol